Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Size Forecast: Revenue and CAGR by 2029
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Industry By The Forecast Year 2029?
The artificial intelligence (AI)-powered rare disease diagnosis market has witnessed significant growth in recent years. It is anticipated to expand from $1.54 billion in 2024 to $1.99 billion in 2025, achieving a compound annual growth rate (CAGR) of 29.1%. Historically, this expansion has been driven by the increasing integration of artificial intelligence (AI) in healthcare, heightened investment in rare disease research, greater recognition of the importance of early diagnosis, improvements in healthcare infrastructure, and enhanced government support for digital health initiatives.
The market size for artificial intelligence (AI)-powered rare disease diagnosis is predicted to experience significant expansion in the coming years. It is projected to achieve a value of $5.50 billion by 2029, expanding at a compound annual growth rate (CAGR) of 28.9%. This anticipated growth during the forecast period stems from factors such as the increasing incorporation of machine learning algorithms, the rising need for personalized medicine, enhanced collaboration between AI startups and hospitals, the broadened availability of genomic data, and the accelerating digitalization of healthcare. Noteworthy trends during this same period encompass advancements in deep learning models, new innovations in predictive diagnostics, progress in natural language processing specifically for medical data, continuous research and development in multi-omics integration, and ongoing refinements in artificial intelligence (AI)-driven imaging technologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28139&type=smp
Which Drivers Are Impacting The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market?
The escalating occurrence of autoimmune disorders is anticipated to fuel the expansion of the artificial intelligence (AI)-powered rare disease diagnosis market. Autoimmune disorders are conditions where the immune system erroneously attacks the body’s healthy cells and tissues, leading to inflammation and damage. The increasing prevalence of these disorders stems from a rising number of individuals experiencing immune system dysfunctions, which in turn drives a higher demand for early diagnosis, advanced treatments, and continuous monitoring to effectively manage symptoms. Artificial intelligence (AI)-powered rare disease diagnosis supports the management of autoimmune disorders by swiftly identifying complex conditions, aiding in personalized treatment decisions, and improving overall diagnostic accuracy. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government organization, in 2022, an estimated 514,000 people (2.0%) in Australia were living with rheumatoid arthritis (a systemic autoimmune disorder in which the body’s immune system targets its tissues). Consequently, the growing prevalence of autoimmune disorders is a significant driver for the growth of the artificial intelligence (AI)-powered rare disease diagnosis market.
What Are The Emerging Segments Gaining Attention In The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market?
The artificial intelligence (AI)-powered rare disease diagnosis market covered in this report is segmented as
1) By Component: Software, Hardware, Services
2) By Technology: Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Other Technologies
3) By Deployment Mode: Cloud-Based, On-Premises
4) By Diagnosis Type: Genetic Disorders, Autoimmune Disorders, Metabolic Disorders, Infectious Diseases, Other Diagnosis Types
5) By End-User: Hospitals, Diagnostic Centers, Research Institutes, Specialty Clinics, Other End-Users
Subsegments:
1) By Software: Clinical Decision Support, Data Analytics Platforms, Genomic Interpretation Tools, Machine Learning Algorithms, Diagnostic Reporting Software
2) By Hardware: Sequencing Instruments, Imaging Devices, Laboratory Equipment, Computational Servers, Diagnostic Sensors
3) By Services: Consulting Services, Implementation And Integration, Training And Support, Data Management Services, Maintenance And Upgrades
What Are The Major Trends Driving The Growth Of The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market?
Leading companies within the artificial intelligence (AI)-powered rare disease diagnosis market are concentrating on developing advanced technologies, such as unified genomic diagnostics solutions, to boost diagnostic precision, shorten turnaround times, and offer more extensive understanding of complex genetic conditions. A unified genomic diagnostics solution functions as a combined system, integrating whole-genome sequencing with artificial intelligence (AI)-driven analysis to provide comprehensive genetic information. For example, in October 2023, Oxford Nanopore Technologies plc, a UK-based biotechnology company, and Fabric Genomics Inc., a US-based artificial intelligence (AI)-based company, introduced an integrated whole-genome sequencing solution designed to speed up rare disease diagnosis. This is achieved by merging rapid sequencing with AI-driven variant interpretation, leading to more precise and practical clinical insights. This new offering brings together real-time nanopore sequencing with artificial intelligence (AI)-powered genomic analysis, facilitating the swift identification of rare genetic variants. It subsequently furnishes clinicians with exhaustive, actionable insights, thereby improving diagnostic speed and accuracy, particularly in pediatric care.
Who Are The Major Companies Operating In The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market?
Major companies operating in the artificial intelligence (ai)-powered rare disease diagnosis market are Ambry Genetics Corporation, MedGenome Inc., Sophia Genetics SA, Variantyx Inc., Facial Dysmorphology Novel Analysis, Atropos Health Inc., Congenica Ltd., Saventic Care Sp. z o.o., Rapid Innovation LLC, Centogene N.V., Impilo AB, ThinkGenetic Inc., ClairLabs Ltd., 3billion Inc., OpenEvidence Inc., GenomeUp S.R.L., Mendel.ai Inc., RareSum GmbH, DeepRare AI Solutions, Zebra-Llama Project.
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Industry Expansion?
North America was the largest region in the artificial intelligence (AI)-powered rare disease diagnosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in artificial intelligence (AI)-powered rare disease diagnosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Report:
https://www.thebusinessresearchcompany.com/customise?id=28139&type=smp
Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market 2025, By The Business Research Company
Artificial Intelligence In Healthcare Diagnosis Global Market Report 2025
Artificial Intelligence In The Diagnostic Global Market Report 2025
Ai In Medical Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
